vs
德康医疗（DXCM）与Regions Financial Corporation（RF）财务数据对比。点击上方公司名可切换其他公司
Regions Financial Corporation的季度营收约是德康医疗的1.5倍（$1.9B vs $1.3B），Regions Financial Corporation净利率更高（29.8% vs 21.2%，领先8.6%），德康医疗同比增速更快（21.6% vs 5.0%），过去两年Regions Financial Corporation的营收复合增速更高（25.7% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Regions Financial Corporation是美国银行控股企业，总部位于阿拉巴马州伯明翰市。公司提供零售及商业银行、信托、股票经纪、抵押贷款等服务，旗下银行业务子公司Regions Bank在美国南部和中西部15个州运营约1300家营业网点和2000台自动柜员机，服务大量当地个人及企业客户。
DXCM vs RF — 直观对比
营收规模更大
RF
是对方的1.5倍
$1.3B
营收增速更快
DXCM
高出16.6%
5.0%
净利率更高
RF
高出8.6%
21.2%
两年增速更快
RF
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.9B |
| 净利润 | $267.3M | $559.0M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | — |
| 净利率 | 21.2% | 29.8% |
| 营收同比 | 21.6% | 5.0% |
| 净利润同比 | 153.6% | — |
| 每股收益（稀释后） | $0.67 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMRF
| Q1 26 | $1.3B | $1.9B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $994.2M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B |
净利润DXCMRF
| Q1 26 | $267.3M | $559.0M | ||
| Q4 25 | $267.3M | $534.0M | ||
| Q3 25 | $283.8M | $569.0M | ||
| Q2 25 | $179.8M | $563.0M | ||
| Q1 25 | $105.4M | $490.0M | ||
| Q4 24 | $151.7M | $534.0M | ||
| Q3 24 | $134.6M | $490.0M | ||
| Q2 24 | $143.5M | $501.0M |
毛利率DXCMRF
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMRF
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 55.3% | ||
| Q3 25 | 20.1% | 56.3% | ||
| Q2 25 | 18.4% | 56.1% | ||
| Q1 25 | 12.9% | 52.0% | ||
| Q4 24 | 17.0% | 53.4% | ||
| Q3 24 | 15.3% | 49.9% | ||
| Q2 24 | 15.7% | 52.7% |
净利率DXCMRF
| Q1 26 | 21.2% | 29.8% | ||
| Q4 25 | 21.2% | 41.7% | ||
| Q3 25 | 23.5% | 45.3% | ||
| Q2 25 | 15.5% | 44.7% | ||
| Q1 25 | 10.2% | 41.0% | ||
| Q4 24 | 13.6% | 43.4% | ||
| Q3 24 | 13.5% | 40.2% | ||
| Q2 24 | 14.3% | 42.2% |
每股收益（稀释后）DXCMRF
| Q1 26 | $0.67 | $0.62 | ||
| Q4 25 | $0.67 | $0.59 | ||
| Q3 25 | $0.70 | $0.61 | ||
| Q2 25 | $0.45 | $0.59 | ||
| Q1 25 | $0.27 | $0.51 | ||
| Q4 24 | $0.37 | $0.55 | ||
| Q3 24 | $0.34 | $0.49 | ||
| Q2 24 | $0.35 | $0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $2.7B | $18.8B |
| 总资产 | $6.3B | $160.7B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资DXCMRF
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $904.9M | — | ||
| Q4 24 | $606.1M | — | ||
| Q3 24 | $621.2M | — | ||
| Q2 24 | $939.2M | — |
总债务DXCMRF
| Q1 26 | — | $6.3B | ||
| Q4 25 | — | $4.1B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.3B | ||
| Q1 25 | — | $6.0B | ||
| Q4 24 | — | $6.0B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $5.1B |
股东权益DXCMRF
| Q1 26 | $2.7B | $18.8B | ||
| Q4 25 | $2.7B | $19.0B | ||
| Q3 25 | $2.7B | $19.0B | ||
| Q2 25 | $2.6B | $18.7B | ||
| Q1 25 | $2.3B | $18.5B | ||
| Q4 24 | $2.1B | $17.9B | ||
| Q3 24 | $2.0B | $18.7B | ||
| Q2 24 | $2.4B | $17.2B |
总资产DXCMRF
| Q1 26 | $6.3B | $160.7B | ||
| Q4 25 | $6.3B | $158.8B | ||
| Q3 25 | $7.5B | $159.9B | ||
| Q2 25 | $7.3B | $159.2B | ||
| Q1 25 | $6.8B | $159.8B | ||
| Q4 24 | $6.5B | $157.3B | ||
| Q3 24 | $6.4B | $157.4B | ||
| Q2 24 | $6.8B | $154.1B |
负债/权益比DXCMRF
| Q1 26 | — | 0.34× | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.25× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
